Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$38.3 million.

  • Stoke Therapeutics' Consolidated Net Income fell 4508.89% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 13826.23%. This contributed to the annual value of -$88.7 million for FY2024, which is 1538.26% up from last year.
  • Stoke Therapeutics' Consolidated Net Income amounted to -$38.3 million in Q3 2025, which was down 4508.89% from -$23.5 million recorded in Q2 2025.
  • Stoke Therapeutics' Consolidated Net Income's 5-year high stood at $112.9 million during Q1 2025, with a 5-year trough of -$38.3 million in Q3 2025.
  • In the last 4 years, Stoke Therapeutics' Consolidated Net Income had a median value of -$25.7 million in 2024 and averaged -$16.3 million.
  • Within the past 5 years, the most significant YoY rise in Stoke Therapeutics' Consolidated Net Income was 52799.35% (2025), while the steepest drop was 4508.89% (2025).
  • Over the past 4 years, Stoke Therapeutics' Consolidated Net Income (Quarter) stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 258.95% to -$38.3 million in 2025.
  • Its Consolidated Net Income stands at -$38.3 million for Q3 2025, versus -$23.5 million for Q2 2025 and $112.9 million for Q1 2025.